Health Risks to Workers Associated With Occupational Exposures to Peracetic Acid; Request for Information, 12819-12821 [2017-04319]
Download as PDF
Federal Register / Vol. 82, No. 43 / Tuesday, March 7, 2017 / Notices
owned by the bank holding company,
including the companies listed below.
The applications listed below, as well
as other related filings required by the
Board, are available for immediate
inspection at the Federal Reserve Bank
indicated. The applications will also be
available for inspection at the offices of
the Board of Governors. Interested
persons may express their views in
writing on the standards enumerated in
the BHC Act (12 U.S.C. 1842(c)). If the
proposal also involves the acquisition of
a nonbanking company, the review also
includes whether the acquisition of the
nonbanking company complies with the
standards in section 4 of the BHC Act
(12 U.S.C. 1843). Unless otherwise
noted, nonbanking activities will be
conducted throughout the United States.
Unless otherwise noted, comments
regarding each of these applications
must be received at the Reserve Bank
indicated or the offices of the Board of
Governors not later than March 29,
2017.
A. Federal Reserve Bank of Chicago
(Colette A. Fried, Assistant Vice
President) 230 South LaSalle Street,
Chicago, Illinois 60690–1414:
1. First Busey Corporation,
Champaign, Illinois; to acquire 100
percent of First Community Financial
Partners, Inc., Joliet, Illinois, and
thereby indirectly acquire First
Community Financial Bank, Plainfield,
Illinois.
B. Federal Reserve Bank of St. Louis
(David L. Hubbard, Senior Manager)
P.O. Box 442, St. Louis, Missouri
63166–2034. Comments can also be sent
electronically to
Comments.applications@stls.frb.org:
1. Miles Bancshares, Inc., Advance,
Missouri; to acquire up to 5.31 percent
of the voting shares of UBT Bancshares,
Inc., Marysville, Kansas, and thereby
indirectly acquire United Bank & Trust,
Marysville, Kansas.
Board of Governors of the Federal Reserve
System, March 1, 2017.
Yao-Chin Chao,
Assistant Secretary of the Board.
[FR Doc. 2017–04314 Filed 3–6–17; 8:45 am]
BILLING CODE 6210–01–P
that are considered in acting on the
notices are set forth in paragraph 7 of
the Act (12 U.S.C. 1817(j)(7)).
The notices are available for
immediate inspection at the Federal
Reserve Bank indicated. The notices
also will be available for inspection at
the offices of the Board of Governors.
Interested persons may express their
views in writing to the Reserve Bank
indicated for that notice or to the offices
of the Board of Governors. Comments
must be received not later than March
20, 2017.
Federal Reserve Bank of Minneapolis
(Jacquelyn K. Brunmeier, Assistant Vice
President) 90 Hennepin Avenue,
Minneapolis, Minnesota 55480–0291:
1. Alerus Financial Employee Stock
Ownership Plan, Grand Forks, North
Dakota; to acquire additional shares of
Alerus Financial Corporation, Grand
Forks, North Dakota, and indirectly
acquire additional shares of Alerus
Financial, National Association, Grand
Forks, North Dakota.
Board of Governors of the Federal Reserve
System, March 2, 2017.
Yao-Chin Chao,
Assistant Secretary of the Board.
[FR Doc. 2017–04449 Filed 3–6–17; 8:45 am]
BILLING CODE 6210–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[Docket Number CDC–2017–0015, NIOSH–
295]
Health Risks to Workers Associated
With Occupational Exposures to
Peracetic Acid; Request for
Information
National Institute for
Occupational Safety and Health
(NIOSH) of the Centers for Disease
Control and Prevention (CDC),
Department of Health and Human
Services (HHS).
ACTION: Request for information.
AGENCY:
The National Institute for
Occupational Safety and Health of the
Centers for Disease Control and
Prevention intends to evaluate the
scientific and technical data on
occupational exposures to peracetic acid
(CAS #79–21–0, also known as
peroxyacetic acid and PAA). NIOSH is
requesting information on the following:
(1) Workplace exposure data for
peracetic acid, (2) possible health effects
observed in workers exposed to
peracetic acid, (3) workplaces and
SUMMARY:
sradovich on DSK3GMQ082PROD with NOTICES
FEDERAL RESERVE SYSTEM
Change in Bank Control Notices;
Acquisitions of Shares of a Bank or
Bank Holding Company
The notificants listed below have
applied under the Change in Bank
Control Act (12 U.S.C. 1817(j)) and
§ 225.41 of the Board’s Regulation Y (12
CFR 225.41) to acquire shares of a bank
or bank holding company. The factors
VerDate Sep<11>2014
16:01 Mar 06, 2017
Jkt 241001
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
12819
products in which peracetic acid may be
found, (4) description of work tasks and
scenarios with a potential for exposure
to peracetic acid, (5) reports and
findings from in vitro and in vivo
toxicity studies with peracetic acid, (6)
data applicable to the quantitative risk
assessment of health effects associated
with acute, subchronic and chronic
workplace exposures to peracetic acid,
(7) sampling and analytical methods for
peracetic acid, and (8) control measures,
including engineering controls, work
practices, and personal protective
equipment (PPE), that are being used in
workplaces where there is potential for
exposure to peracetic acid.
DATES: Electronic or written comments
must be received by June 5, 2017.
ADDRESSES: You may submit comments,
identified by CDC–2017–0015 and
docket number NIOSH–295, by any of
the following methods:
• Federal eRulemaking Portal: https://
www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: National Institute for
Occupational Safety and Health, NIOSH
Docket Office, 1090 Tusculum Avenue,
MS C–34, Cincinnati, Ohio 45226–1998.
Instructions: All information received
in response to this notice must include
the agency name and docket number
[CDC–2017–0015; NIOSH–295]. All
relevant comments received will be
posted without change to
www.regulations.gov, including any
personal information provided. For
access to the docket to read background
documents or comments received, go to
www.regulations.gov.
FOR FURTHER INFORMATION CONTACT: G.
Scott Dotson, NIOSH, Education and
Information Division, Robert A. Taft
Laboratories, 1090 Tusculum Avenue,
Cincinnati, OH 45226, (513) 533–8540
(not a toll free number).
SUPPLEMENTARY INFORMATION: Peracetic
acid is a peroxide-based molecule used
extensively as an antimicrobial agent in
many commercial applications. It is
routinely used as a sterilant during the
cleaning of endoscopes and other
medical devices, as a disinfectant in
food processing, as a bleaching agent,
and in the synthesis of other chemicals
[NAS 2010; Pechacek et al. 2015]. The
chemical and physical properties of
peracetic acid make the molecule highly
reactive, unstable, and volatile.
Peracetic acid has a pungent, vinegarlike odor [NAS 2010].
Peracetic acid is formed from a
sulfuric acid-catalyzed chemical
reaction between acetic acid and
hydrogen peroxide [NAS 2010].
Peracetic acid solutions typically
consist of a mixture of peracetic acid,
E:\FR\FM\07MRN1.SGM
07MRN1
12820
Federal Register / Vol. 82, No. 43 / Tuesday, March 7, 2017 / Notices
acetic acid, and hydrogen peroxide in
various concentrations. NAS [2010]
reported that technical or commercial
peracetic acid products contain
peracetic acid, acetic acid, and
hydrogen peroxide in solution.
Concentrations of peracetic acid in these
products vary, but do not exceed 40%.
Peracetic acid products containing more
than 15% peracetic acid demonstrate
excessive reactivity, instability, and
some degree of explosiveness [Pechacek
et al. 2015].
Acute exposure to peracetic acid is
irritating to the eyes, respiratory tract,
and skin. Peracetic acid is a strong
sensory irritant considered to be more
potent than acetic acid or hydrogen
peroxide [NAS 2010]. CristofariMargquand et al. [2007] indicated that
healthcare workers experienced asthma
associated with workplace exposures to
peracetic acid. No data on human
lethality due to exposure to peracetic
acid were identified. Lethal exposures
in animals caused hemorrhage, edema,
and pulmonary consolidation [NAS
2010].
NIOSH does not have a recommended
exposure limit (REL) for peracetic acid.
The Occupational Safety and Health
Administration (OSHA) has not
established a permissible exposure limit
(PEL). The California Division of
Occupational Safety and Health
(CalOSHA) has not established a PEL for
peracetic acid. The American
Conference of Governmental Industrial
Hygienists (ACGIH®) has established a
threshold limit value (TLV®)—short
term exposure limit (STEL) of 1.24 mg/
m3 (0.4 ppm) to protect workers against
irritation of eyes, skin, and the upper
respiratory tract [ACGIH® 2016]. The
National Advisory Committee for Acute
Exposure Guideline Levels for
Hazardous Substances (NAC/AEGL
Committee) has established AEGL
values for peracetic acid [NAS 2010].
AEGL values are threshold exposure
limits for the general public and are
applicable to emergency exposure
periods ranging from 10 minutes to 8
hours [NAS 2001]. AEGL–1 represents
an airborne concentration above which
exposures could cause notable
discomfort, irritation, or certain
asymptomatic non-sensory effects.
AEGL–2 represents an airborne
concentration above which exposures
could cause irreversible or other serious,
long lasting adverse effects or an
impaired ability to escape. AEGL–3
represents an airborne concentration
above which exposures could cause lifethreatening effects or death. Table 1
summarizes the AEGL values for
peracetic acid.
TABLE 1—AEGL VALUES FOR PERACETIC ACID *
10 minute
AEGL–1 ...................................
AEGL–2 ...................................
AEGL–3 ...................................
30 minute
mg/m 3
0.52
(0.17 ppm)
1.6 mg/m 3 (0.5 ppm)
3 (19 ppm)
60 mg/m
mg/m 3
0.52
(0.17 ppm)
1.6 mg/m 3 (0.5 ppm)
3 (9.6 ppm)
30 mg/m
60 minute
mg/m 3
0.52
(0.17 ppm)
1.6 mg/m 3 (0.5 ppm)
3 (4.8 ppm)
15 mg/m
4 hour
mg/m 3
0.52
(0.17 ppm)
1.6 mg/m 3 (0.5 ppm)
3 (2 ppm)
6.3 mg/m
8 hour
0.52 mg/m 3 (0.17 ppm).
1.6 mg/m 3 (0.5 ppm).
4.1 mg/m 3 (1.3 ppm).
sradovich on DSK3GMQ082PROD with NOTICES
* NAS [2010].
In May 2015, NIOSH published a
notice in the Federal Register [80 FR
24930] announcing the availability of
and a request for comments for the draft
immediately dangerous to life or health
(IDLH) values and support technical
documents, entitled Immediately
Dangerous to Life or Health (IDLH)
Value Profiles, for 14 chemicals
including peracetic acid. The proposed
IDLH value for peracetic acid was 1.7
mg/m3 (0.55 ppm) [draft NIOSH 2015].
The proposed recommendation was
based on sensory irritation in human
volunteers reported in Fraser and
Thorbinson [1986]. Due to subsequent
requests from the public, a
supplemental notice was published in
the Federal Register [81 FR 53147]
announcing that NIOSH was seeking
further comments on the draft IDLH
Value Profile for peracetic acid. The
public comments indicated that (1) the
proposed IDLH value was
overprotective, (2) the data available for
peracetic acid are of low quality, and (3)
issues exist with the sampling and
analysis of air samples for peracetic acid
in the workplace. Based on these
comments, NIOSH is re-evaluating the
proposed IDLH value for peracetic acid.
Research efforts are needed to
characterize the acute and chronic
health effects of occupational exposures
to peracetic acid. These efforts include:
(1) Epidemiological and field studies
VerDate Sep<11>2014
16:01 Mar 06, 2017
Jkt 241001
designed to assess workplace exposures
to peracetic acid, (2) in vivo and in vitro
studies designed to characterize the
acute, sub-chronic, and chronic effects
of peracetic acid, (3) quantitative risk
assessment(s) intended to characterize
the increased risks associated with
workplace exposures to peracetic acid,
(4) evaluation of workplace controls,
including engineering controls,
administrative controls, and PPE, (5)
development of analytical methods to
accurately collect and analyze air
samples of peracetic acid under various
conditions (e.g., task-based monitoring,
full-shift monitoring, real-time
monitoring).
Background: The purpose of the RFI
is to seek information relevant to
assessing the risk of occupational
exposures to peracetic acid.
Information Needs: Additional data
and information are needed to assist
NIOSH in characterizing and assessing
the health risk of occupational
exposures to peracetic acid. Information
is needed on: (1) Workplace exposure
data for peracetic acid, (2) possible
health effects observed in workers
exposed to peracetic acid, (3)
workplaces and products in which
peracetic acid may be found, (4)
description of work tasks and scenarios
with a potential for exposure to
peracetic acid, (5) reports and findings
from in vitro and in vivo toxicity studies
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
with peracetic acid, (6) data applicable
to the quantitative risk assessment of
health effects associated with acute,
subchronic and chronic workplace
exposures to peracetic acid, (7)
sampling and analytical methods for
peracetic acid, and (8) control measures,
including engineering controls, work
practices, and personal protective
equipment (PPE), that are being used in
workplaces where there is potential for
exposure to peracetic acid.
References
ACGIH® (American Conference of
Governmental Industrial Hygienists)
[2016]. Annual TLVs® (Threshold Limit
4 Values) and BEIs® (Biological Exposure
Indices) booklet. Cincinnati, OH:
ACGIH® Signature Publications.
Cristofari-Marquand E, Kacel M, Milhe F,
Magnan A, Lehucher-Michel MP [2007].
Asthma caused by peracetic acidhydrogen peroxide mixture. J Occup
Health 49(2):155–158.
Fraser JAL, Thorbinson A [1986]. Fogging
trials with Tenneco Organics Limited
(30th June, 1986) at Collards Farm.
Solvay Interox. Warington, United
Kingdom.
NAS (National Academies of Science) [2001].
Standing operating procedures for
developing acute exposure guidelines
levels for hazardous chemicals.
Washington, DC: National Academy
Press. [https://www.epa.gov/sites/
production/files/2015-09/documents/
sop_final_standing_operating_
procedures_2001.pdf].
E:\FR\FM\07MRN1.SGM
07MRN1
Federal Register / Vol. 82, No. 43 / Tuesday, March 7, 2017 / Notices
NAS [2010]. Chapter 7: peracetic acid-acute
exposure guideline levels. In: acute
exposure guideline levels for selected
airborne chemicals: volume 8. [https://
www.epa.gov/opptintr/aegl/pubs/
peracetic_acid_final_volume8_2010.pdf].
NIOSH (National Institute for Occupational
Safety and Health) [draft 2015].
Immediately dangerous to life or health
(IDLH) value profile for peracetic acid.
External review draft (Dated: March
2015). [https://www.cdc.gov/niosh/
docket/review/docket156a/pdfs/g1-013peracetic-acid-cas-79-21-0.pdf].
Pechacek N, Osorio M, Caudill J, Peterson B
[2015]. Evaluation of the toxicity data for
peracetic acid in deriving occupational
exposure limits: A minireview.
Toxicology Letters 233: 45–57.
Dated: March 1, 2017.
Frank Hearl,
Chief of Staff, National Institute for
Occupational Safety and Health, Centers for
Disease Control and Prevention.
Officer, CDC, 4770 Buford Highway,
Mailstop F80, Atlanta, Georgia 30341,
Telephone: (770) 488–6511, kva5@
cdc.gov delegated the authority to sign
Federal Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2017–04354 Filed 3–6–17; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Center for Complementary
and Integrative Health; Notice of
Closed Meeting
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
sradovich on DSK3GMQ082PROD with NOTICES
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Initial Review
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces a meeting for the initial
review of applications in response to
Funding Opportunity Announcement
(FOA) DP15–0020301SUPP17,
Supplement to Enhance Laboratory and
Statistical Support of the Population
Registry of Diabetes in Youth.
TIME AND DATE: 11:00 a.m.–2:00 p.m.,
EDT, March 29, 2017 (Closed).
PLACE: Teleconference.
STATUS: The meeting will be closed to
the public in accordance with
provisions set forth in Section 552b(c)
(4) and (6), Title 5 U.S.C., and the
Determination of the Director,
Management Analysis and Services
Office, CDC, pursuant to Public Law 92–
463.
MATTERS FOR DISCUSSION: The meeting
will include the initial review,
discussion, and evaluation of
applications received in response to
‘‘Supplement to Enhance Laboratory
and Statistical Support of the
Population Registry of Diabetes in
Youth’’, FOA DP15–0020301SUPP17.
CONTACT PERSON FOR MORE INFORMATION:
Jaya Raman Ph.D., Scientific Review
VerDate Sep<11>2014
16:01 Mar 06, 2017
Jkt 241001
Dated: March 1, 2017.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–04325 Filed 3–6–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
BILLING CODE 4163–18–P
[FR Doc. 2017–04319 Filed 3–6–17; 8:45 am]
BILLING CODE 4163–18–P
12821
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Center for
Complementary and Integrative Health
Special Emphasis Panel; NIH Health Care
Systems Research Collaboratory—
Coordinating Center (U24).
Date: April 6, 2017.
Time: 12:00 p.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Viatcheslav A.
Soldatenkov, Ph.D., Scientific Review
Officer, Office of Scientific Review, Division
of Extramural Activities, NCCIH/NIH, 6707
Democracy Blvd., Suite 401, Bethesda, MD
20892, 301–451–3849, sOLDATENKOVV@
mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.213, Research and Training
in Complementary and Integrative Health,
National Institutes of Health, HHS)
PO 00000
Frm 00040
Fmt 4703
Sfmt 9990
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIH Support for
Conferences and Scientific Meetings (Parent
R13).
Date: March 20–22, 2017.
Time: 8:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
Contact Person: J. Bruce Sundstrom, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
Room 3G11A, National Institutes of Health/
NIAID, 5601 Fishers Lane, MSC 9823,
Bethesda, MD 20892–9823, 240–669–5045,
sundstromj@niaid.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the urgent
need to meet timing limitations imposed by
the intramural research review cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: March 1, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–04326 Filed 3–6–17; 8:45 am]
BILLING CODE 4140–01–P
E:\FR\FM\07MRN1.SGM
07MRN1
Agencies
[Federal Register Volume 82, Number 43 (Tuesday, March 7, 2017)]
[Notices]
[Pages 12819-12821]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-04319]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[Docket Number CDC-2017-0015, NIOSH-295]
Health Risks to Workers Associated With Occupational Exposures to
Peracetic Acid; Request for Information
AGENCY: National Institute for Occupational Safety and Health (NIOSH)
of the Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Request for information.
-----------------------------------------------------------------------
SUMMARY: The National Institute for Occupational Safety and Health of
the Centers for Disease Control and Prevention intends to evaluate the
scientific and technical data on occupational exposures to peracetic
acid (CAS #79-21-0, also known as peroxyacetic acid and PAA). NIOSH is
requesting information on the following: (1) Workplace exposure data
for peracetic acid, (2) possible health effects observed in workers
exposed to peracetic acid, (3) workplaces and products in which
peracetic acid may be found, (4) description of work tasks and
scenarios with a potential for exposure to peracetic acid, (5) reports
and findings from in vitro and in vivo toxicity studies with peracetic
acid, (6) data applicable to the quantitative risk assessment of health
effects associated with acute, subchronic and chronic workplace
exposures to peracetic acid, (7) sampling and analytical methods for
peracetic acid, and (8) control measures, including engineering
controls, work practices, and personal protective equipment (PPE), that
are being used in workplaces where there is potential for exposure to
peracetic acid.
DATES: Electronic or written comments must be received by June 5, 2017.
ADDRESSES: You may submit comments, identified by CDC-2017-0015 and
docket number NIOSH-295, by any of the following methods:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments.
Mail: National Institute for Occupational Safety and
Health, NIOSH Docket Office, 1090 Tusculum Avenue, MS C-34, Cincinnati,
Ohio 45226-1998.
Instructions: All information received in response to this notice
must include the agency name and docket number [CDC-2017-0015; NIOSH-
295]. All relevant comments received will be posted without change to
www.regulations.gov, including any personal information provided. For
access to the docket to read background documents or comments received,
go to www.regulations.gov.
FOR FURTHER INFORMATION CONTACT: G. Scott Dotson, NIOSH, Education and
Information Division, Robert A. Taft Laboratories, 1090 Tusculum
Avenue, Cincinnati, OH 45226, (513) 533-8540 (not a toll free number).
SUPPLEMENTARY INFORMATION: Peracetic acid is a peroxide-based molecule
used extensively as an antimicrobial agent in many commercial
applications. It is routinely used as a sterilant during the cleaning
of endoscopes and other medical devices, as a disinfectant in food
processing, as a bleaching agent, and in the synthesis of other
chemicals [NAS 2010; Pechacek et al. 2015]. The chemical and physical
properties of peracetic acid make the molecule highly reactive,
unstable, and volatile. Peracetic acid has a pungent, vinegar-like odor
[NAS 2010].
Peracetic acid is formed from a sulfuric acid-catalyzed chemical
reaction between acetic acid and hydrogen peroxide [NAS 2010].
Peracetic acid solutions typically consist of a mixture of peracetic
acid,
[[Page 12820]]
acetic acid, and hydrogen peroxide in various concentrations. NAS
[2010] reported that technical or commercial peracetic acid products
contain peracetic acid, acetic acid, and hydrogen peroxide in solution.
Concentrations of peracetic acid in these products vary, but do not
exceed 40%. Peracetic acid products containing more than 15% peracetic
acid demonstrate excessive reactivity, instability, and some degree of
explosiveness [Pechacek et al. 2015].
Acute exposure to peracetic acid is irritating to the eyes,
respiratory tract, and skin. Peracetic acid is a strong sensory
irritant considered to be more potent than acetic acid or hydrogen
peroxide [NAS 2010]. Cristofari-Margquand et al. [2007] indicated that
healthcare workers experienced asthma associated with workplace
exposures to peracetic acid. No data on human lethality due to exposure
to peracetic acid were identified. Lethal exposures in animals caused
hemorrhage, edema, and pulmonary consolidation [NAS 2010].
NIOSH does not have a recommended exposure limit (REL) for
peracetic acid. The Occupational Safety and Health Administration
(OSHA) has not established a permissible exposure limit (PEL). The
California Division of Occupational Safety and Health (CalOSHA) has not
established a PEL for peracetic acid. The American Conference of
Governmental Industrial Hygienists (ACGIH[supreg]) has established a
threshold limit value (TLV[supreg])--short term exposure limit (STEL)
of 1.24 mg/m\3\ (0.4 ppm) to protect workers against irritation of
eyes, skin, and the upper respiratory tract [ACGIH[supreg] 2016]. The
National Advisory Committee for Acute Exposure Guideline Levels for
Hazardous Substances (NAC/AEGL Committee) has established AEGL values
for peracetic acid [NAS 2010]. AEGL values are threshold exposure
limits for the general public and are applicable to emergency exposure
periods ranging from 10 minutes to 8 hours [NAS 2001]. AEGL-1
represents an airborne concentration above which exposures could cause
notable discomfort, irritation, or certain asymptomatic non-sensory
effects. AEGL-2 represents an airborne concentration above which
exposures could cause irreversible or other serious, long lasting
adverse effects or an impaired ability to escape. AEGL-3 represents an
airborne concentration above which exposures could cause life-
threatening effects or death. Table 1 summarizes the AEGL values for
peracetic acid.
Table 1--AEGL Values for Peracetic Acid *
--------------------------------------------------------------------------------------------------------------------------------------------------------
10 minute 30 minute 60 minute 4 hour 8 hour
--------------------------------------------------------------------------------------------------------------------------------------------------------
AEGL-1............................... 0.52 mg/m \3\ (0.17 0.52 mg/m \3\ (0.17 0.52 mg/m \3\ (0.17 0.52 mg/m \3\ (0.17 0.52 mg/m \3\ (0.17
ppm) ppm) ppm) ppm) ppm).
AEGL-2............................... 1.6 mg/m \3\ (0.5 1.6 mg/m \3\ (0.5 1.6 mg/m \3\ (0.5 1.6 mg/m \3\ (0.5 1.6 mg/m \3\ (0.5
ppm) ppm) ppm) ppm) ppm).
AEGL-3............................... 60 mg/m \3\ (19 ppm) 30 mg/m \3\ (9.6 ppm) 15 mg/m \3\ (4.8 ppm) 6.3 mg/m \3\ (2 ppm) 4.1 mg/m \3\ (1.3
ppm).
--------------------------------------------------------------------------------------------------------------------------------------------------------
* NAS [2010].
In May 2015, NIOSH published a notice in the Federal Register [80
FR 24930] announcing the availability of and a request for comments for
the draft immediately dangerous to life or health (IDLH) values and
support technical documents, entitled Immediately Dangerous to Life or
Health (IDLH) Value Profiles, for 14 chemicals including peracetic
acid. The proposed IDLH value for peracetic acid was 1.7 mg/m\3\ (0.55
ppm) [draft NIOSH 2015]. The proposed recommendation was based on
sensory irritation in human volunteers reported in Fraser and
Thorbinson [1986]. Due to subsequent requests from the public, a
supplemental notice was published in the Federal Register [81 FR 53147]
announcing that NIOSH was seeking further comments on the draft IDLH
Value Profile for peracetic acid. The public comments indicated that
(1) the proposed IDLH value was overprotective, (2) the data available
for peracetic acid are of low quality, and (3) issues exist with the
sampling and analysis of air samples for peracetic acid in the
workplace. Based on these comments, NIOSH is re-evaluating the proposed
IDLH value for peracetic acid.
Research efforts are needed to characterize the acute and chronic
health effects of occupational exposures to peracetic acid. These
efforts include: (1) Epidemiological and field studies designed to
assess workplace exposures to peracetic acid, (2) in vivo and in vitro
studies designed to characterize the acute, sub-chronic, and chronic
effects of peracetic acid, (3) quantitative risk assessment(s) intended
to characterize the increased risks associated with workplace exposures
to peracetic acid, (4) evaluation of workplace controls, including
engineering controls, administrative controls, and PPE, (5) development
of analytical methods to accurately collect and analyze air samples of
peracetic acid under various conditions (e.g., task-based monitoring,
full-shift monitoring, real-time monitoring).
Background: The purpose of the RFI is to seek information relevant
to assessing the risk of occupational exposures to peracetic acid.
Information Needs: Additional data and information are needed to
assist NIOSH in characterizing and assessing the health risk of
occupational exposures to peracetic acid. Information is needed on: (1)
Workplace exposure data for peracetic acid, (2) possible health effects
observed in workers exposed to peracetic acid, (3) workplaces and
products in which peracetic acid may be found, (4) description of work
tasks and scenarios with a potential for exposure to peracetic acid,
(5) reports and findings from in vitro and in vivo toxicity studies
with peracetic acid, (6) data applicable to the quantitative risk
assessment of health effects associated with acute, subchronic and
chronic workplace exposures to peracetic acid, (7) sampling and
analytical methods for peracetic acid, and (8) control measures,
including engineering controls, work practices, and personal protective
equipment (PPE), that are being used in workplaces where there is
potential for exposure to peracetic acid.
References
ACGIH[supreg] (American Conference of Governmental Industrial
Hygienists) [2016]. Annual TLVs[supreg] (Threshold Limit 4 Values)
and BEIs[supreg] (Biological Exposure Indices) booklet. Cincinnati,
OH: ACGIH[supreg] Signature Publications.
Cristofari-Marquand E, Kacel M, Milhe F, Magnan A, Lehucher-Michel
MP [2007]. Asthma caused by peracetic acid-hydrogen peroxide
mixture. J Occup Health 49(2):155-158.
Fraser JAL, Thorbinson A [1986]. Fogging trials with Tenneco
Organics Limited (30th June, 1986) at Collards Farm. Solvay Interox.
Warington, United Kingdom.
NAS (National Academies of Science) [2001]. Standing operating
procedures for developing acute exposure guidelines levels for
hazardous chemicals. Washington, DC: National Academy Press.
[https://www.epa.gov/sites/production/files/2015-09/documents/sop_final_standing_operating_procedures_2001.pdf].
[[Page 12821]]
NAS [2010]. Chapter 7: peracetic acid-acute exposure guideline
levels. In: acute exposure guideline levels for selected airborne
chemicals: volume 8. [https://www.epa.gov/opptintr/aegl/pubs/peracetic_acid_final_volume8_2010.pdf].
NIOSH (National Institute for Occupational Safety and Health) [draft
2015]. Immediately dangerous to life or health (IDLH) value profile
for peracetic acid. External review draft (Dated: March 2015).
[https://www.cdc.gov/niosh/docket/review/docket156a/pdfs/g1-013-peracetic-acid-cas-79-21-0.pdf].
Pechacek N, Osorio M, Caudill J, Peterson B [2015]. Evaluation of
the toxicity data for peracetic acid in deriving occupational
exposure limits: A minireview. Toxicology Letters 233: 45-57.
Dated: March 1, 2017.
Frank Hearl,
Chief of Staff, National Institute for Occupational Safety and Health,
Centers for Disease Control and Prevention.
[FR Doc. 2017-04319 Filed 3-6-17; 8:45 am]
BILLING CODE 4163-18-P